exRNAdisease

General Information

Database ID:

exR0088982

RNA Name:

hsa-miR-513a-5p

RNA Type:

miRNA

Chromosome:

chrX

Starnd:

Coordinate:

Start Site(bp):

147213538

End Site(bp):

147213555

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AEN	chr15	88621337	88632281	+
CD276	chr15	73683966	73714514	+
FAM168B	chr2	131047876	131093460	-
GIPC1	chr19	14477760	14496149	-
IGF2BP3	chr7	23310209	23470491	-
ILF3	chr19	10654261	10692417	+
JRK	chr8	142657460	142681968	-
KCTD21	chr11	78171249	78188626	-
KIAA0232	chr4	6781375	6884170	+
MET	chr7	116672196	116798386	+
MTCL1	chr18	8705661	8832778	+
NRBP1	chr2	27427790	27442259	+
PA2G4	chr12	56104537	56113910	+
PAK1	chr11	77321707	77474635	-
PLK2	chr5	58453982	58460139	-
PPP1CC	chr12	110719680	110742939	-
PRLR	chr5	35048756	35230487	-
RHOU	chr1	228735479	228746664	+
SNX27	chr1	151612006	151699091	+
SOX11	chr2	5692384	5701385	+
SS18	chr18	26016253	26091217	-
STRBP	chr9	123109500	123268586	-
TMX4	chr20	7977346	8019805	-
TXN2	chr22	36467046	36481640	-
WASL	chr7	123681943	123749003	-

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000894	chr19	12825634	12826553	-
hsa_circ_0000540	chr14	55799534	55821940	+
hsa_circ_0001005	chr2	53921020	53978078	-
hsa_circ_0001168	chr20	47691321	47707559	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC009133.5	chr16	29808679	29812227	+
AC023509.1	chr12	53441741	53467528	+
AC095055.1	chr4	151139991	151141103	+
AC239868.1	chr1	149861271	149862504	+
CYTOR	chr2	87454781	87636740	+
KCNQ1OT1	chr11	2608328	2699994	-
LINC01578	chr15	92819540	92899701	+
MIR4435-2HG	chr2	111006015	111523376	-
MIR663AHG	chr20	26167817	26251546	-
NEAT1	chr11	65422774	65445540	+
OIP5-AS1	chr15	41283990	41309737	+
SNHG16	chr17	76557764	76565348	+
SNHG20	chr17	77086716	77099902	+

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.